These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23412108)

  • 21. Phase I study of the antiangiogenic antibody bevacizumab and the mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with liposomal doxorubicin: tolerance and biological activity.
    Moroney J; Fu S; Moulder S; Falchook G; Helgason T; Levenback C; Hong D; Naing A; Wheler J; Kurzrock R
    Clin Cancer Res; 2012 Oct; 18(20):5796-805. PubMed ID: 22927482
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma.
    Lamhamedi-Cherradi SE; Menegaz BA; Ramamoorthy V; Vishwamitra D; Wang Y; Maywald RL; Buford AS; Fokt I; Skora S; Wang J; Naing A; Lazar AJ; Rohren EM; Daw NC; Subbiah V; Benjamin RS; Ratan R; Priebe W; Mikos AG; Amin HM; Ludwig JA
    J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27576731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
    Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
    Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
    Shin DH; Min HY; El-Naggar AK; Lippman SM; Glisson B; Lee HY
    Mol Cancer Ther; 2011 Dec; 10(12):2437-48. PubMed ID: 21980128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies.
    Trivedi ND; Armstrong S; Wang H; Hartley M; Deeken J; Ruth He A; Subramaniam D; Melville H; Albanese C; Marshall JL; Hwang J; Pishvaian MJ
    Cancer Med; 2021 Mar; 10(6):1944-1954. PubMed ID: 33638305
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers.
    Khawaja MR; Nick AM; Madhusudanannair V; Fu S; Hong D; McQuinn LM; Ng CS; Piha-Paul SA; Janku F; Subbiah V; Tsimberidou A; Karp D; Meric-Bernstam F; Lu KH; Naing A
    Cancer Chemother Pharmacol; 2016 May; 77(5):973-7. PubMed ID: 27014780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.
    Liu X; Kambrick S; Fu S; Naing A; Subbiah V; Blumenschein GR; Glisson BS; Kies MS; Tsimberidou AM; Wheler JJ; Zinner RG; Hong DS; Kurzrock R; Piha-Paul SA
    Oncotarget; 2016 Apr; 7(17):23227-38. PubMed ID: 26933802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group.
    Weigel B; Malempati S; Reid JM; Voss SD; Cho SY; Chen HX; Krailo M; Villaluna D; Adamson PC; Blaney SM
    Pediatr Blood Cancer; 2014 Mar; 61(3):452-6. PubMed ID: 23956055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.
    Schöffski P; Adkins D; Blay JY; Gil T; Elias AD; Rutkowski P; Pennock GK; Youssoufian H; Gelderblom H; Willey R; Grebennik DO
    Eur J Cancer; 2013 Oct; 49(15):3219-28. PubMed ID: 23835252
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy.
    Gradishar WJ; Yardley DA; Layman R; Sparano JA; Chuang E; Northfelt DW; Schwartz GN; Youssoufian H; Tang S; Novosiadly R; Forest A; Nguyen TS; Cosaert J; Grebennik D; Haluska P
    Clin Cancer Res; 2016 Jan; 22(2):301-9. PubMed ID: 26324738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
    Hussain M; Rathkopf D; Liu G; Armstrong A; Kelly WK; Ferrari A; Hainsworth J; Joshi A; Hozak RR; Yang L; Schwartz JD; Higano CS
    Eur J Cancer; 2015 Sep; 51(13):1714-24. PubMed ID: 26082390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
    Alvarez EA; Brady WE; Walker JL; Rotmensch J; Zhou XC; Kendrick JE; Yamada SD; Schilder JM; Cohn DE; Harrison CR; Moore KN; Aghajanian C
    Gynecol Oncol; 2013 Apr; 129(1):22-7. PubMed ID: 23262204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
    J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 study of the insulin-like growth factor-1 receptor inhibitor MK-0646 in patients with metastatic, well-differentiated neuroendocrine tumors.
    Reidy-Lagunes DL; Vakiani E; Segal MF; Hollywood EM; Tang LH; Solit DB; Pietanza MC; Capanu M; Saltz LB
    Cancer; 2012 Oct; 118(19):4795-800. PubMed ID: 22437754
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
    Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
    Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
    Park H; Williams K; Trikalinos NA; Larson S; Tan B; Waqar S; Suresh R; Morgensztern D; Van Tine BA; Govindan R; Luo J; Lockhart AC; Wang-Gillam A
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):337-347. PubMed ID: 33159216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma.
    Haluska P; Worden F; Olmos D; Yin D; Schteingart D; Batzel GN; Paccagnella ML; de Bono JS; Gualberto A; Hammer GD
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):765-73. PubMed ID: 19649631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN Cancer Research Group (E2804).
    Flaherty KT; Manola JB; Pins M; McDermott DF; Atkins MB; Dutcher JJ; George DJ; Margolin KA; DiPaola RS
    J Clin Oncol; 2015 Jul; 33(21):2384-91. PubMed ID: 26077237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.